ASH 2022 | Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Pere Barba
• 12 Dec 2022
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain, describes the findings of a Phase I study that assessed the toxicity and efficacy induced by rapcabtagene autoleucel (YTB323) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT03960840). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Allogene, Amgen, BMS, Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar and Novartis: Consultancy.
